Clinical Pharmacy Education Improved Infection Management In Chronic Kidney Disease

Published May 17, 2013
Medan, Indonesia - Chronic kidney disease (CKD) remains a global public health problem due to its increasing prevalence, poor outcomes, low treatment rate, and high costs. However, clinical pharmacy education (CPE) can improve outcomes and optimize health care costs. A quasi-experimental economic evaluation comparing CPE impact on six-months mortality of JAMKESMAS-insured stage 4 and 5 CKD patients was conducted in Haji Adam Malik Hospital, Indonesia. The group of CKD patients that received care by health care providers that were given CPE on drug related problems (DRPs) and dose adjustment had lower cost-effectiveness (CE) ratios compared to those without CPE. Active roles of clinical pharmacists in patient care in HAM Hospital, Medan, Indonesia, improve outcomes and reduce costs for the treatment of infection in CKD stage 4 and 5. This study evaluated the impacts of clinical pharmacy education (CPE) on efficiency and effectiveness of infection management among patients with chronic kidney disease (CKD) stage 4 and 5 in Haji Adam Malik (HAM) Hospital, Indonesia. Treatment of CKD stage 4 and 5 with CPE was more effective and cost-effective compared to those without CPE. There were more lives-saved (88.89%) in treatment of stage 4 CKD patients with CPE compared to those without CPE (78.57%). There were also more lives-saved (65.45%) in treatment of stage 5 CKD patients with CPE compared to those without CPE (57.58%). Dr. Nasution, coauthor of this study, quoted "This study suggests that active contribution of pharmacists in the management of CKD patients improve efficiency and effectiveness."
Value in Health Regional Issues  (ISSN 2212-1099) is a scientific journal that encourages and enhances the science of pharmacoeconomic/health economic and health outcomes research and its use in health care decisions. The journal is published up to three times a year with one issue focusing on the Asia region, one issue focusing on the Latin America region, and one issue focusing on the Central & Eastern Europe, Western Asia and Africa regions. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

Related Stories

Value in Health Regional Issues Expands Editorial Scope and Reveals Plans to Transition to Gold Open Access Model

Jan 23, 2024

Value in Health Regional Issues, an official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the expansion of its editorial scope and its plan to transition to a gold open access journal.

Empowering Change: Transforming Health Systems in Low- and Middle-Income Countries

Jan 22, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health Regional Issues that highlight innovative approaches to improving health outcomes in low- and middle-income countries through partnerships between health economics researchers and policy makers.

ISPOR’s Value in Health Regional Issues Receives Its First Impact Factor Score

Aug 7, 2023

Value in Health Regional Issues, the regionally focused journal of ISPOR, received its first-ever impact factor score this year. Value in Health, one of the top-ranked journals in the HEOR field, maintained its high ranking on the prestigious list of scholarly journals.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now